title: Potential hazards to embryo implantation: A human endometrial in vitro model to identify unwanted antigestagenic actions of chemicals.
abstract: Embryo implantation is a crucial step in human reproduction and depends on the timely development of a receptive endometrium. The human endometrium is unique among adult tissues due to its dynamic alterations during each menstrual cycle. It hosts the implantation process which is governed by progesterone, whereas 17β-estradiol regulates the preceding proliferation of the endometrium. The receptors for both steroids are targets for drugs and endocrine disrupting chemicals. Chemicals with unwanted antigestagenic actions are potentially hazardous to embryo implantation since many pharmaceutical antiprogestins adversely affect endometrial receptivity. This risk can be addressed by human tissue-specific in vitro assays. As working basis we compiled data on chemicals interacting with the PR. In our experimental work, we developed a flexible in vitro model based on human endometrial Ishikawa cells. Effects of antiprogestin compounds on pre-selected target genes were characterized by sigmoidal concentration-response curves obtained by RT-qPCR. The estrogen sulfotransferase (SULT1E1) was identified as the most responsive target gene by microarray analysis. The agonistic effect of progesterone on SULT1E1 mRNA was concentration-dependently antagonized by RU486 (mifepristone) and ZK137316 and, with lower potency, by 4-nonylphenol, bisphenol A and apigenin. The negative control methyl acetoacetate showed no effect. The effects of progesterone and RU486 were confirmed on the protein level by Western blotting. We demonstrated proof of principle that our Ishikawa model is suitable to study quantitatively effects of antiprogestin-like chemicals on endometrial target genes in comparison to pharmaceutical reference compounds. This test is useful for hazard identification and may contribute to reduce animal studies.
authors.affiliation: Department of Obstetrics & Gynecology, University Hospital Freiburg, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Fischer
authors.forename: W R
authors.initials: WR
authors.lastname: Deppert
authors.forename: D
authors.initials: D
authors.lastname: Pfeifer
authors.forename: S
authors.initials: S
authors.lastname: Stanzel
authors.forename: M
authors.initials: M
authors.lastname: Weimer
authors.forename: A
authors.initials: A
authors.lastname: Hanjalic-Beck
authors.forename: A
authors.initials: A
authors.lastname: Stein
authors.forename: M
authors.initials: M
authors.lastname: Straßer
authors.forename: H P
authors.initials: HP
authors.lastname: Zahradnik
authors.forename: W R
authors.initials: WR
authors.lastname: Schaefer
mesh_terms: D000328:Adult; D015153:Blotting, Western; D002478:Cells, Cultured; D064420:Drug-Related Side Effects and Adverse Reactions; D010064:Embryo Implantation / Q000187:drug effects*; D052244:Endocrine Disruptors / Q000633:toxicity; D004717:Endometrium / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D006727:Hormone Antagonists / Q000633:toxicity; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis; D011374:Progesterone / Q000378:metabolism* / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D015238:Sulfotransferases / Q000235:genetics; D018675:Toxicity Tests / Q000379:methods*
chemical_list: D052244:Endocrine Disruptors; D006727:Hormone Antagonists; D012333:RNA, Messenger; D011374:Progesterone; D015238:Sulfotransferases; C020122:estrone sulfotransferase